RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2

TEL AVIV, Israel and RALEIGH, N.C., Sept. 8 (Korea Bizwire) – RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that opaganib1 demonstrated potent inhibition of SARS-CoV-2, the virus that causes COVID-19, achieving complete blockage of viral replication in an in vitro model of human lung bronchial tissue. Opaganib is a first-in-class, orally-administered, sphingosine kinase-2 (SK2) [...]